bacteria were mutating so fast that even the most spectacular new products couldn’t keep up
Тома Крутенкоhas quoted5 years ago
these companies are accountable to shareholders, not patients
Тома Крутенкоhas quoted5 years ago
For antibacterial drugs, the NPV is approximately $42 million; for most other products—including muscular and neurologic drugs—the number is closer to $1 billion.